Dianthus (DNTH) director receives 6,090 options vesting by 2027

Rhea-AI Filing Summary

Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.

The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Read Simon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,090	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,090 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 6,090 options Exercise price: 89.63 per share Underlying shares: 6,090 shares +2 more

5 metrics

Options granted 6,090 options Stock option award to director on May 21, 2026

Exercise price 89.63 per share Exercise price of granted stock options

Underlying shares 6,090 shares Common stock underlying the options

Expiration date May 21, 2036 Options expire if not exercised by this date

Post-grant derivative holdings 6,090 options Total derivative position following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 89.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-21T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"award will vest in full on the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders, subject to service"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Read Simon

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$89.63	05/21/2026		A		6,090		(1)	05/21/2036	Common Stock	6,090	$0	6,090	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Adam Veness, as attorney-in-fact for Simon Read	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dianthus Therapeutics (DNTH) director Simon Read report on this Form 4?

Director Simon Read reported receiving a grant of 6,090 stock options. These options are a compensation-related award, not an open-market trade, and give him the right to buy Dianthus Therapeutics common stock if and when the options vest and are exercised.

How many Dianthus Therapeutics (DNTH) stock options were granted and what do they cover?

The filing shows a grant of 6,090 stock options. Each option is a right to buy one share of Dianthus Therapeutics common stock, so the award covers 6,090 underlying shares if fully vested and exercised under the terms of the grant.

When do Simon Read’s Dianthus (DNTH) stock options vest?

The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholders’ meeting. Vesting is conditional on Simon Read’s continued service to Dianthus Therapeutics through that vesting date, according to the footnote.

What is the exercise price and expiration date of the Dianthus (DNTH) options?

The stock options have an exercise price of 89.63 per share and an expiration date of May 21, 2036. After expiration, any unexercised options become worthless, so potential value depends on future stock price and timely exercise once vested.

Does this Dianthus (DNTH) Form 4 indicate insider buying or selling in the market?

This Form 4 reports a grant of stock options as compensation, not a market buy or sell. No open-market purchases or sales are disclosed; instead, the company awarded options that may be exercised in the future once vested, at the stated exercise price.